H.C. Wainwright analyst Robert Burns raised the firm’s price target on Adicet Bio (ACET) to $9 from $4 and keeps a Buy rating on the shares. The firm views ADI-001’s profile as “extremely attractive” in both lupus nephritis and systemic lupus erythematosus.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Inc. Reports Q3 2025 Financial Results
- Adicet Bio reports Q3 EPS , consensus (32c)
- Adicet Bio reports Q3 EPS (29c), consensus (32c)
- Adicet Bio doses first patient in ADI-001 trial
- Adicet Bio’s Promising Off-the-Shelf Cell Therapy Garners Buy Rating Due to Positive Clinical Outcomes and Strong Market Position